Lonza China multi-party renewable PPA with Envision Energy
This project is operational in China. The source does not give a quantified reduction for this project.
- Status
- Operational
- Estimated reduction
- Not quantified in the source
- Countries
- China
- Sector
- Renewable power
- Announced
- 17 January 2024
- Expected start
- 2024
About this project
The description is as the source gives it.
Lonza joined AstraZeneca, Novartis, Novo Nordisk and Roche in a three-year multi-party renewable power purchase agreement with Envision Energy for approximately 200 GWh annually of renewable electricity (wind and solar) starting 2024 for operations in China. This supports decarbonization of Lonza's Scope 2 emissions in its Chinese sites. Evidence: "AstraZeneca, Lonza, Novartis, Novo Nordisk and Roche sign agreement in China with green technology company Envision Energy to unlock access to renewable power, resulting in potential annual carbon dioxide equivalent savings of around 120,000 tonnes." — https://www.sustainable-markets.org/news/five-global-healthcare-leaders-secure-industry-first-multi-party-agreement-to-access-renewable-power-in-china
Statuses, countries and reductions are as the public source states them, and may be out of date.
Project developers can list this project on Carbon3
Project developers can list a project on Carbon3, so that buyers and co-funders can see it. Listing a project costs nothing.